Activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) is an inborn error of immunity that manifests as immune deficiency and dysregulation; symptoms include frequent infections and lymphoproliferation. In our dose-finding and phase 3 placebo-controlled trials, treatment with the selective PI3Kδ inhibitor leniolisib reduced lymphoproliferation and normalized lymphocyte subsets. Here, we present 6 years of follow-up from the 6 adult patients in the original dose-finding trial receiving leniolisib. We used data from the ongoing open-label extension study, which was supplemented at later time points by investigators, including health-related quality of life (HRQoL) assessed through a clinician-reported questionnaire. We observed improvements in HRQoL: 5 of 6 patients experienced an increase in physical capabilities and socialization, and a decrease in prescribed medications. Immune subsets improved in all patients: mean transitional B-cell levels decreased from 38.17% to 2.47% and the CD4:CD8 T-cell ratio normalized to 1.11. Manifestations seen before and within the first year of leniolisib exposure, such as infections and gastrointestinal conditions, attenuated after year 2, with few new conditions emerging out to year 6. Thrombocytopenia or lymphopenia remained present in half of patients at year 6. Of 83 adverse events through year 5, 90.36% were grade 1; none were grade 4/5 nor deemed leniolisib related. Collectively, we saw an enhancement in HRQoL as well as durable changes in lymphocyte subsets and clinical manifestations, further supporting the use of leniolisib as a long-term therapeutic option for the treatment of APDS. This trial was registered at www.ClinicalTrials.gov as #NCT02859727.

Alberta Health Services Calgary AB Canada

Clinical Research Directorate Frederick National Laboratory for Cancer Research Bethesda MD

Department of Immunology 2nd Faculty of Medicine Charles University and Motol University Hospital Prague Czech Republic

Division of Allergy and Clinical Immunology and Department of Immunology Department of Internal Medicine Erasmus MC University Medical Center Rotterdam The Netherlands

Division of Allergy and Immunology University of Pittsburgh Medical Center Children's Hospital of Pittsburgh Pittsburgh PA

Division of Hematology Children's Hospital of Orange County Orange CA

National Institute of Allergy and Infectious Diseases National Institutes of Health Bethesda MD

Pharming Healthcare Inc Warren NJ

Zobrazit více v PubMed

Angulo I, Vadas O, Garcon F, et al. Phosphoinositide 3-kinase delta gene mutation predisposes to respiratory infection and airway damage. Science. 2013;342(6160):866–871. PubMed PMC

Lucas CL, Kuehn HS, Zhao F, et al. Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110delta result in T cell senescence and human immunodeficiency. Nat Immunol. 2014;15(1):88–97. PubMed PMC

Lucas CL, Zhang Y, Venida A, et al. Heterozygous splice mutation in PIK3R1 causes human immunodeficiency with lymphoproliferation due to dominant activation of PI3K. J Exp Med. 2014;211(13):2537–2547. PubMed PMC

Coulter TI, Chandra A, Bacon CM, et al. Clinical spectrum and features of activated phosphoinositide 3-kinase delta syndrome: a large patient cohort study. J Allergy Clin Immunol. 2017;139(2):597–606.e4. PubMed PMC

Elkaim E, Neven B, Bruneau J, et al. Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase delta syndrome 2: a cohort study. J Allergy Clin Immunol. 2016;138(1):210–218.e9. PubMed

Nunes-Santos CJ, Uzel G, Rosenzweig SD. PI3K pathway defects leading to immunodeficiency and immune dysregulation. J Allergy Clin Immunol. 2019;143(5):1676–1687. PubMed

Coulter TI, Cant AJ. The treatment of activated PI3Kdelta syndrome. Front Immunol. 2018;9:1–5. PubMed PMC

Maccari ME, Abolhassani H, Aghamohammadi A, et al. Disease evolution and response to rapamycin in activated phosphoinositide 3-kinase delta syndrome: the European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase delta Syndrome Registry. Front Immunol. 2018;9:1–8. PubMed PMC

Oh J, Garabedian E, Fuleihan R, Cunningham-Rundles C. Clinical manifestations and outcomes of activated phosphoinositide 3-kinase delta syndrome from the USIDNET Cohort. J Allergy Clin Immunol Pract. 2021;9(11):4095–4102. PubMed PMC

Durandy A, Kracker S. Increased activation of PI3 kinase-delta predisposes to B-cell lymphoma. Blood. 2020;135(9):638–643. PubMed

Edwards ESJ, Bier J, Cole TS, et al. Activating PIK3CD mutations impair human cytotoxic lymphocyte differentiation and function and EBV immunity. J Allergy Clin Immunol. 2019;143(1):276–291.e6. PubMed

Seeborg FO, Seay R, Boyle M, Boyle J, Scalchunes C, Orange JS. Perceived health in patients with primary immune deficiency. J Clin Immunol. 2015;35(7):638–650. PubMed PMC

Lum A, Wakefield CE, Donnan B, et al. School students with chronic illness have unmet academic, social, and emotional school needs. Sch Psychol. 2019;34(6):627–636. PubMed

Sexson SB, Madan-Swain A. School reentry for the child with chronic illness. J Learn Disabil. 1993;26(2):115–137. 137. PubMed

Shiu S. Issues in the education of students with chronic illness. Int J Disabil Dev Educ. 2001;48(3):269–281.

Megari K. Quality of life in chronic disease patients. Health Psychol Res. 2013;1(3):e27. PubMed PMC

Ward BW. Multiple chronic conditions and labor force outcomes: a population study of U.S. adults. Am J Ind Med. 2015;58(9):943–954. PubMed PMC

Anderson JT, Cowan J, Condino-Neto A, Levy D, Prusty S. Health-related quality of life in primary immunodeficiencies: impact of delayed diagnosis and treatment burden. Clin Immunol. 2022;236:1–10. PubMed

Jiang F, Torgerson TR, Ayars AG. Health-related quality of life in patients with primary immunodeficiency disease. Allergy Asthma Clin Immunol. 2015;11:1–11. PubMed PMC

Rao VK, Webster S, Dalm V, et al. Effective "activated PI3Kdelta syndrome"-targeted therapy with the PI3Kdelta inhibitor leniolisib. Blood. 2017;130(21):2307–2316. PubMed PMC

Rao VK, Webster S, Sediva A, et al. A randomized, placebo-controlled phase 3 trial of the PI3Kdelta inhibitor leniolisib for activated PI3Kdelta syndrome. Blood. 2023;141(9):971–983. PubMed PMC

Rao VK, Kulm E, Sediva A, et al. Interim analysis: open-label extension study of leniolisib for patients with APDS. J Allergy Clin Immunol. 2024;153(1):265–274.e9. PubMed PMC

Ballow M, Conaway MR, Sriaroon P, et al. Construction and validation of a novel disease-specific quality-of-life instrument for patients with primary antibody deficiency disease (PADQOL-16) J Allergy Clin Immunol. 2017;139(6):2007–2010.e8. PubMed

Quinti I, Pulvirenti F, Giannantoni P, et al. Development and initial validation of a questionnaire to measure health-related quality of life of adults with common variable immune deficiency: the CVID_QoL Questionnaire. J Allergy Clin Immunol Pract. 2016;4(6):1169–1179.e4. PubMed

Routes J, Costa-Carvalho BT, Grimbacher B, et al. Health-related quality of life and health resource utilization in patients with primary immunodeficiency disease prior to and following 12 months of immunoglobulin G treatment. J Clin Immunol. 2016;36(5):450–461. PubMed PMC

Maruish ME. Quality Metric Incorporated; 2011. User's Manual for the SF-36v2 Health Survey.

Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579–586. PubMed

Linguraru MG, Sandberg JK, Jones EC, Summers RM. Assessing splenomegaly: automated volumetric analysis of the spleen. Acad Radiol. 2013;20(6):675–684. PubMed PMC

Morbach H, Eichhorn EM, Liese JG, Girschick HJ. Reference values for B cell subpopulations from infancy to adulthood. Clin Exp Immunol. 2010;162(2):271–279. PubMed PMC

van Gent R, van Tilburg CM, Nibbelke EE, et al. Refined characterization and reference values of the pediatric T- and B-cell compartments. Clin Immunol. 2009;133(1):95–107. PubMed

Laboratory Corporation of America Immunoglobulin G, Quantitative. https://www.labcorp.com/tests/001776/immunoglobulin-g-quantitative Updated 2021.

Laboratory Corporation of America Immunoglobulin A, Quantitative. https://www.labcorp.com/tests/001784/immunoglobulin-a-quantitative Updated 2021.

Laboratory Corporation of America Immunoglobulin M, Quantitative. https://www.labcorp.com/tests/001792/immunoglobulin-m-quantitative Updated 2021.

Laboratory Corporation of America Immunoglobulin E, Total. https://www.labcorp.com/tests/002170/immunoglobulin-e-total Updated 2021.

Li H, Dummer JS, Estes WR, Meng S, Wright PF, Tang YW. Measurement of human cytomegalovirus loads by quantitative real-time PCR for monitoring clinical intervention in transplant recipients. J Clin Microbiol. 2003;41(1):187–191. PubMed PMC

Lin JC, Wang WY, Chen KY, et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med. 2004;350(24):2461–2470. PubMed

Laboratory Corporation of America Immunoglobulin G, Subclass 1. https://www.labcorp.com/tests/160507/immunoglobulin-g-subclass-1 Updated 2021.

Laboratory Corporation of America Immunoglobulin G, Subclass 2. https://www.labcorp.com/tests/160515/immunoglobulin-g-subclass-2 Updated 2021.

Laboratory Corporation of America Immunoglobulin G, Subclass 3. https://www.labcorp.com/tests/160523/immunoglobulin-g-subclass-3 Updated 2021.

Laboratory Corporation of America Immunoglobulin G, Subclass 4. https://www.labcorp.com/tests/160531/immunoglobulin-g-subclass-4 Updated 2021.

Gardulf A, Nicolay U, Math D, et al. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol. 2004;114(4):936–942. PubMed

Kuburovic NB, Pasic S, Susic G, et al. Health-related quality of life, anxiety, and depressive symptoms in children with primary immunodeficiencies. Patient Prefer Adherence. 2014;8:323–330. PubMed PMC

Tabolli S, Giannantoni P, Pulvirenti F, et al. Longitudinal study on health-related quality of life in a cohort of 96 patients with common variable immune deficiencies. Front Immunol. 2014;5:1–9. PubMed PMC

Albert MH, Sirait T, Eikema DJ, et al. Hematopoietic stem cell transplantation for adolescents and adults with inborn errors of immunity: an EBMT IEWP study. Blood. 2022;140(14):1635–1649. PubMed

Dimitrova D, Nademi Z, Maccari ME, et al. International retrospective study of allogeneic hematopoietic cell transplantation for activated PI3K-delta syndrome. J Allergy Clin Immunol. 2022;149(1):410–421.e7. PubMed PMC

Hoegenauer K, Soldermann N, Zecri F, et al. Discovery of CDZ173 (leniolisib), representing a structurally novel class of PI3K delta-selective inhibitors. ACS Med Chem Lett. 2017;8(9):975–980. PubMed PMC

Zobrazit více v PubMed

ClinicalTrials.gov
NCT02859727